icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
San Francisco
November 2018
Back grey_arrow_rt.gif
High SVR in PWID with HCV Despite Imperfect
Medication Adherence: Data from the ANCHOR Study

  I am reporting in real time live from AASLD bringing you since Nov 9 the very most pertinent and oral presentations to out community and to people with HCV, and the most important studies showing the strong & potent efficacy & high SVR rates for treatment & therapy and the key research that is reporting the clinical & population benefits of HCV treatment: improved survival & health, the cost savings & effectiveness of treatment & more so early treatment, and very importantly the study that reports modeling showing that we are NOT on a good course to even approach thinking we are on a path to HCV elimination in the USA. In fact the study reports 4% treatment rates in the NHAHNES populations in a study on HCV cascade of care, and even in the better groups where the cascade is better, the NHAHNES groups treatment rates are not near where they need to be, and the study authors report we will not come close to HCV elimination at these rtes, and I of course have been saying these very same words for years. Of course one of the most marginalized groups are PWID, without implementing a screening & linkage to care & support services treatment program for this group which is very heterogeneous we will never begin to approach HCV elimination. Support services for PWID are needed to provide the best opportunity to cure PWIDs. The HERO study is a long term large national study on which I sit that studies DOT, direct observed therapy to PWIDs, this is one potential solution to adherence. Not to address the needs of HCV elimination in this patient group defeats the purpose & prevents us from trying to reach HCV elimination. In HIV it took 5 years after HAART inception in 1996 to agree to treat PWIDs, can you imaging today telling the community PWIDs could not get HIV treatment, of course this would never happen. We provide support services for them, and HCV should be no different. The costs for HIV treatment are MUCH greater than for HCV treatment, the ineptitude of local, state and federal officials in not addressing treating PWIDs is only due to political pressure. In HIV that pressure succeeded, there is not enough pressure in HCV. Government decision makers treat HIV & aging similarly, we need services for aging disabled HIV+ yet they refuse to address this. Its a disgrace, and shows you the cowardice & incompetency of our health officials leadership in HIV and HCV. Jules
Reported by Jules Levin
AASLD 2018 SF Nov 9-13
Sarah Kattakuzhy MD, Poonam Mathur DO MPH, Chloe Gross RN, Rachel Silk RN MPH, Elizabeth Akoth RN MPH, Kristi Hill BA, Laura Nussdorf BA, Nadeera Sidique BA, Chloe Chaudhury BS, David Sternberg BA, Henry Masur MD, Shyamasundaran Kottilil MD PhD, Elana Rosenthal MD NIH DC Partnership for HIV/AIDS Progress
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
video on study results, author interview: https://www.youtube.com/watch?v=e6SVzv7IL8w